Biomarker analysis of neoadjuvant doxorubicin/ cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1587-1595

  Horak, Christine E ^a   Pusztai, Lajos ^b   Xing, Guan ^a   Trifan, Ovidiu C ^a   Saura, Cristina ^c   Tseng, Ling Ming ^d   Chan, Stephen ^e   Welcher, Rosanne ^f   Liu, David ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b YALE CANCER CENTER   (United States)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f AGILENT TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA3 TUBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; IXABEPILONE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CAPG GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TACC3 GENE; TUBB3 GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPOTHILONES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROFILAMENT PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; PROGNOSIS; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84875184938     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1359     Document Type: Article

References (57)

1. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin 2009;59:303-13.
2. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 2010;23 Suppl 2:S60-4.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
4. RouzierR,PerouCM,SymmansWF, IbrahimN,CristofanilliM,Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
5. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61.
6. Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010;19:246-8.
7. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
8. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26: 1275-81.
9. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, et al. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 2008;26:806-13.
10. Snoj N, Bedard PL, de Azambuja E, Cardoso F, Piccart M. Are we HERting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res 2009;11:201.
11. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
12. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updaters of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
13. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010;124:689-99.
14. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23:1169-77.
15. Nagasaki K, Miki Y. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer 2008; 15:117-20.
16. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22: 2284-93.
17. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006;99:9-17.
18. Kadra G, Finetti P, Toiron Y, Viens P, Birnbaum D, Borg JP, et al. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Res Treat 2012;132:1035-47.
19. Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, et al. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer 2011;47:1779-88.
20. Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, et al. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 2011;117:3682-90.
21. Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. MC Med Genomics 2011;4:3.
22. Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, et al.Agene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2010;123:691-9.
23. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010;119:551-8.
24. Rody A, Karn T, G€atje R, Ahr A, Solbach C, Kourtis K, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 2007;16: 86-93.
25. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006;24:1839-45.
26. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23:7265-77.
27. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment of breast cancer. J Clin Oncol 2009;27:526-34.
28. Gradishar WJ, Wedam SB, Jahanzeb M, Erban J, Limentani SA, Tsai KT, et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005;16:1297-304.
29. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-7.
30. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7: 3025-30.
31. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.
32. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-12.
33. Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting bIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009; 8:17-25.
34. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered b-tubulin isotype expression in pacltiaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77:562-6.
35. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III b-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:1020-5.
36. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III b-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-56.
37. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005;16 Suppl 4:14-9.
38. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, et al. Cytoskeleton and paclitaxel-sensitivity in breast cancer: the role of b-tubulins. Int J Cancer 2007;120:2078-85.
39. Sève P, Dumontet C. Is class III b-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-75.
40. Horak CE, Lee FY, Xu L, Galbraith S, Baselga J. High b-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. J Clin Oncol 27:15s, 2009 (suppl; abstr 3587).
41. Wu S, Chasalow S, Lee H, Xu L, Paul B, Mokliatchouk O, et al. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients. J Clin Oncol 25:18s, 2007 (suppl; abstr 2525).
42. Booth DG, Hood FE, Prior IA, Royle SJ. A TACC3/ch-TOG/clathrin complex stabilises kinetochore fibres by inter-microtubule bridging. EMBO J 2011;30:906-19.
43. Hubert T, Van Impe K, Vandekerckhove J, Gettemans J. The actincapping protein CapG localizes to microtubule-dependent organelles during the cell cycle. Biochem Biophys Res Commun 2009;380: 166-70.
44. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 1995;270:31269-75.
45. Bhattacharya R, Cabral F. A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 2004; 15:3123-31.
46. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
47. Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, et al. Expression of class III b-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-6.
48. Sève P, Mackey J, Isaac S, Trédan O, Souquet PJ, Pérol M, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
49. Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, Jakesz R, et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 2003;81:149-57.
50. Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, et al. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 2000;60:3493-503.
51. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22.
52. Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
53. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210-7.
54. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28: 3256-63.
55. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/ HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010;121:261-71.
56. Rugo HS, Campone M, Amadori D, Wardley AM, Aldrighetti D, Conte PF, et al. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results. J Clin Oncol 28:15s, 2010 (suppl; abstr 1040).
57. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30, 2012 (suppl; abstr CRA1002).